Clinuvel Pharmaceuticals (OTCMKTS:CLVLY – Get Free Report) is anticipated to announce its results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.1977 per share and revenue of $25.6640 million for the quarter.
Clinuvel Pharmaceuticals Stock Down 0.4%
CLVLY opened at $8.44 on Wednesday. Clinuvel Pharmaceuticals has a 12 month low of $6.00 and a 12 month high of $9.00. The firm’s fifty day simple moving average is $8.21 and its 200 day simple moving average is $7.85.
Clinuvel Pharmaceuticals Company Profile
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
Featured Articles
- Five stocks we like better than Clinuvel Pharmaceuticals
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- This makes me furious
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
